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ABSTRACT 
Nanoparticles can be used to purify proteins from plasma. We report here the purification of apolipoprotein A-I (apoA-I) 
with high specificity from human plasma using copolymeric nanoparticles. We present an optimized protocol using 
50:50 NiPAM:BAM copolymer nanoparticles with thermo-responsive properties as an affinity resin. Repeated pelleting 
and washing of nanoparticle-captured apoA-I is achieved through temperature cycling. The protein is then eluted using 
urea followed by an ion exchange step for protein concentration and depletion of nanoparticles. 
 
Keywords: Apolipoprotein A-I, Nanoparticles, Selective Purification 
1. Introduction 
The isolation and purification of proteins from complex 
bodily fluids is a challenging task, especially for low 
abundance proteins. The presence of a very high number 
(often several thousands) of other proteins means that 
classical methods like ion exchange chromatography and 
gel filtration yield only partial purification and a large 
number of steps may be needed. Affinity purification pro-
vides a shorter purification route and can lead to much 
simplified purification schemes if an entity with high af-
finity and high specificity for the desired protein is at 
hand. Commonly used entities are peptides, proteins, spe-
cific antibodies or low Mw ligands coupled to chroma-
tography resins. For example, factor IX can be purified 
with vey high specificity from human plasma using con-
formation-specific antibodies that bind solely to the 
metal-stabilized conformer [1]. An example of a low Mw 
ligand is p-aminomethyl-benzene-sulfonamide for affin-
ity purification of carbonic anhydrase [2]. Examples of 
peptides and proteins used successfully in single-step 
purification are the streptococcal IgA-binding peptide for 
human IgA [3], and an affibody, derived from staphylo-
coccal protein A and selected by phage display, for Taq 
DNA polymerase [4]. While antibodies and other protein 
ligands offer very high specificity with excellent purity 
of the isolated protein, the scale-up costs are high be-
cause the required amount of ligand scales linearly with 
batch size. Development of less expensive and more 
versatile tools for affinity purification is therefore still a 
tractable goal. 
Protein purification methods based on nanoparticles 
have recently been developed, especially nickel-ni-tri- lo- 
triacetate modified magnetic nanoparticles for purifying 
poly-His-tagged proteins [5-7]. The magnetism of the 
particles makes the purification extremely easy. However, 
this approach requires engineering of the protein to be 
purified and is not feasible for purification of proteins 
from bodily fluids. Non-tagged proteins may be purified 
using magnetic nanoparticles modified with specific high 
affinity ligands as described above for chromatographic 
resins. 
Here we report the use of thermo-responsive copoly-
mer nanoparticles for protein purification. The special 
properties of NiPAM:BAM copolymer particles allow 
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for repeated precipitation and re-suspension through tem- 
perature cycling, and specific interaction makes it po- 
ssible to purify with high efficiency one specific protein 
from human plasma, apolipoprotein A-I (apoA-I). ApoA-I 
is the major protein constituent of high-density lipopro-
tein (HDL). HDL is involved in reverse cholesterol 
transport and is thought to play an important role in low-
ering the risk of coronary artery disease [8-10]. The tra-
ditional purification of apolipoproteins from plasma is a 
time consuming process [11-15]. The lipoproteins are 
normally isolated from plasma by one or several prepara-
tive ultracentrifugation steps. The purified lipoproteins 
contain a high degree of lipids and several proteins. The 
apolipoproteins are delipified using organic solvents and 
single apolipoproteins are separated from the mixture of 
proteins by biophysical and biochemical methods. This 
process is not protein friendly and takes days if not 
weeks. In contrast, the method presented here can be 
completed in less than 12 hours yielding apoA-I of high 
quality and purity. 
2. Material and Methods 
2.1. 70 nm NIPAM:BAM 50:50 Polymer  
Particles 
N-isopropylacrylamide-N-tert-butylacrylamide (NIPAM: 
BAM) copolymer particles of 70 nm diameter with 50:50 
ratio of the monomers were synthesized in SDS micelles 
by free radical polymerization as described previously 
[16], although higher SDS concentration was used in the 
present work. The procedure for the synthesis was as fo- 
llows: 2.8 g monomers (in the appropriate wt/wt ratio), 
and 0.28 g crosslinker (N,N-methylenebisacrylamide) 
were dissolved in 190 mL MilliQ water with 0.8 g SDS 
and degassed by bubbling with N2 for 30 min. Polymeri-
sation was induced by adding 0.095 g ammonium persul-
fate initiator in 10 mL degassed MilliQ water and heating 
at 70˚C for 4 hours [17]. Particles were extensively dial-
ysed against MilliQ water for several weeks, changing 
the water daily. Particles were lyophilized and stored in 
the fridge until used. 
2.2. Plasma 
Human blood was withdrawn from healthy humans into 
vessels pre-treated with EDTA-solution. The vessels 
where centrifuged for 5 min at 800 Relative Centrifuga-
tion Force (RCF). The supernatants (the plasma) were 
transferred to new vessels and stored in –80˚C freezer 
until the time of use. Before use the plasma vessel was 
thawed and centrifuged for 3 min at 16.1 kRCF and the 
supernatant was transferred to a new vessel, or in the 
case where more than one plasma vessel was needed the 
supernatants were pooled. 
2.3. Particle and Plasma Mixtures 
Stock solutions of particles were made by dispersing 
lyophilized copolymer particles, to a concentration of 10 
mg/mL, in 10 mM Tris/HCl, pH 7.5 with 0.15 mM NaCl 
and 1 mM EDTA or in 10 mM phosphate, pH 7.5 with 
0.15 mM NaCl and 1 mM EDTA. The mixture was kept 
on ice until all the particles were dispersed (1-3 hours) 
before mixing with plasma. After mixing the particles 
and plasma the sample was kept on ice except during the 
centrifugation steps, which were performed at room tem- 
perature. 
In one experiment, lyophilized copolymer particles 
were dissolved directly in plasma by adding plasma to 
the particles and keeping the mixtures on ice for 1 hour. 
2.4. Ion-Exchange Chromatography 
Ion exchange chromatography was performed on a Hi-
Trap DEAE FF 1 mL column from GE Healthcare at 
room temperature in 10 mM Tris/HCl, pH 7.5 with 1 mM 
EDTA (buffer A). Urea fractions (eluates from the nano- 
particles) were pooled and passed through a 0.45 µm 
syringe filter. After filtration the urea and salt concentra-
tions were lowered by ten-fold dilution with buffer A. 
(Alternatively, the salt and urea concentration may be 
lowered by dialysis against buffer A). The sample was 
thereafter loaded onto the column. ApoA-I was eluted by 
stepwise increasing the NaCl concentration: the first step 
was elution with 50 mM NaCl in buffer A to remove the 
nanoparticles; the second step (the elution of apoA-I) is 
performed with 10 0.15 M NaCl in buffer A.  
2.5. SDS-PAGE 
In this study two different SDS-PAGE gels have been 
used: PIERCE, PreciseTM Protein Gels 4% - 20% pre- 
made gel, which are commercially available; and 12% 
gels which were cast immediately prior to use. 
2.6. Commercial ApoA-I 
ApoA-I (A-0722) was obtained from Sigma-Aldrich and 
used as obtained. 
2.7. Biophysical Analysis by UV-, CD- and  
Fluorescence Spectrometry 
The commercial apoA-I (Sigma-Aldrich, A-0722) was 
diluted 10 times with 10 mM phosphate, 0.15 M NaCl, 1 
mM EDTA, pH 7.5, to approximately 0.15 mg/mL which 
corresponds approximately to the concentration of the 
purified apoA-I as estimated from the absorbance at 280 
nm. 
The CD signal between 200 and 260 nm was recorded 
on a Jasco J-720 spectropolarimeter at 25˚C using a 1 
mm quartz cuvette. The fluorescence emission spectra, 
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after excitation at 295 nm, were recorded between 310 
and 400 nm on a Perkin-Elmer luminescence spectrome-
ter LS 50B in a 1 cm quartz cuvette and the UV absorb-
ance spectra were recorded between 250 and 300 in a 1 
cm cuvette. 
2.8. Reconstitution of Phospholipids:ApoA-I  
Vesicles 
Phospholipids vesicles with apoA-I were reconstituted as 
previously described [18]. Briefly, apoA-I was mixed 
with phosphatidyl choline (PC) and minute amounts of 
radio-labelled 14C-POPC PC (260:1 PC/apoA-I molar 
ratio) and dialyzed in order to generate rHDL. The sam-
ple was separated by gel filtration on a Superose 6 col-
umn, and eluted fractions were analyzed by scintillation 
counting and apoA-I content was determined by apoA-I 
ELISA. 
3. Results and Discussion 
The purification scheme is based on the high affinity and 
specificity of 50:50 NiPAM:BAM copolymer nanoparti-
cles for apoA-I [19,20] and the temperature responsive 
behaviour of the nanoparticles. The copolymer particles 
are expanded and mainly dispersed as individual particles 
at temperatures below 10˚C, but collapsed and aggre-
gated (at least if the particle concentration is high enough) 
at temperatures over 10˚C. These properties make the 
50:50 NiPAM:BAM copolymer nanoparticles ideal for 
use in an affinity based purification scheme for apoA-I 
that can be completed within a day, as shown in Scheme 
1. 
3.1. Purification Scheme 
The purification scheme consists of the following steps; 
1) Mixing of copolymer particles with plasma and incu-
bation on ice for 60 minutes (the mixture contains 10 mg 
of 50:50 NiPAM:BAM nanoparticles of 70 nm diameter 
per mL human plasma); 2) Pelleting the particles by 
heating to room temperature and centrifugation for 3 
minutes at 16 kRCF followed by aspiration of the super-
natant (which is discarded); 3) Washing of the pellet by 
addition of 10 mM Tris/HCl pH 7.5, 1 mM EDTA, 150 
mM NaCl, 100 µL per mg of nanoparticles 4) Repeat 
step 2; 5) Repeat step 3; 6) Repeat step 2; 7) Repeat step 
3; 8) Repeat step 2; 9) Elution of bound protein from the 
nanoparticles by addition of 6 M urea, 10 mM Tris/HCl 
pH 7.5, 1 mM EDTA, 100 µL per mg of nanoparticles, 
and incubation on ice for 30 minutes; 10) Pelleting of the 
particles by heating to room temperature and centrifuga-
tion for 3 minutes at 16 kRCF, followed by collection of 
the supernatant (saved for step 15); 11) Repeat step 9; 12) 
Repeat step 10; 13) Repeat step 9; 14) Repeat step 10; 15)  
 
Scheme 1. The approximate experimental run time is indi-
cated at the right-hand side of the chart. 
 
Ten-fold dilution of the eluate (supernatant from steps 10, 
12 and 14) with 10 mM Tris/HCl pH 7.5, 1 mM EDTA, 
and loading onto an DEAE (HiTrap FF) ion-exchange 
column; 16) Washing of the column with 10 mM 
Tris/HCl pH 7.5, 1 mM EDTA, (10 mL per 1 mL resin); 
17) 2nd washing step of the DEAE column using 10 mM 
Tris/HCl pH 7.5, 1 mM EDTA, 50 mM NaCl, (10 mL 
per 1 mL resin); 18) Elution of apoA-I from the DEAE 
column in 10 mM Tris/HCl pH 7.5, 1 mM EDTA, 150 
mM NaCl, (10 mL per 1 mL resin, collection of 1 mL 
fractions). Samples from all steps were analysed by SDS 
PAGE and the samples after steps 5, 7, 9, 11, 13, and 18 
are shown in Figure 1. 
The purification scheme yields pure protein free from 
nanoparticles, and each step has been optimized to pro-
vide the highest yield and the least disruption to the pro-
tein native state. Buffer composition, incubation time, and 
washing conditions were varied during this optimization 
and the amount of apoA-I adsorbed to the co-polymer 
particles was investigated using SDS PAGE.  
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3.2. Role of Salt and Buffer Composition in the 
Nanoparticle-Binding Step 
The results from different incubation conditions for co-
polymer particles with human plasma are shown in Fig-
ure 2. The effect of buffer and salt was evaluated by 
comparing incubation in phosphate- or trizma-based 
buffers at 10 mM, pH 7.5 with 1 mM EDTA, with or 
without 0.15 M NaCl, and all solutions were incubated 
for 1, 3, and 6 hours. The nanoparticle bound apoA-I was 
eluted from the particles with SDS-loading buffer after 
three washing steps (using the same buffer and salt con-
centration as during the respective incubation). The re-
sults (Figure 2) clearly show that the buffer composition 
is important, as more apoA-I is retrieved from particles 
in Tris/HCl buffers than from particles in phosphate 
buffer (Figure 1). The salt concentration is also impor-  
 
 
Figure 1. SDS-PAGE of samples from the different stages of 
the purification of apoA1. Lane 1 = supernatant after the 
2nd wash (step 5), lane 2 = supernatant after the 3rd wash 
(step 7). Lanes 3, 4, and 5 show the supernatants after the 
urea elution steps (9, 11, and 13, respectively). Lane 6 shows 
the eluate of the DEAE ion-exchange column (step 17). The 
left lane contains molecular weight standards with the Mw 
of the proteins given to the left. 
 
 
Figure 2. SDS PAGE investigation of the effects of buffer 
composition and incubation time. In order to study the 
amount of apoA-I bound to the nanoparticles proteins were 
eluted from the nanoparticles into SDS loading buffer after 
three washes using the same buffer as in the incubation step. 
NaP = 10 mM sodium phosphate buffer, pH 7.5, 1 mM 
EDTA; Tris = 10 mM trizma base/HCl, pH 7.5, 1 mM 
EDTA; NaCl = 0.15 M NaCl; Time = incubation time in 
hours. The left lane contains molecular weight standards 
with the Mw of the proteins given to the left. 
tant, and the best buffer condition for the initial incuba-
tion step is 10 mM Tris /HCl, 1 mM EDTA, 0.15 M 
NaCl. We also find that one hour incubation is sufficient 
to maximize the amount of apoA-I bound to the copoly-
mer particles. Longer incubation does not increase the 
amount of apoA-I retrieved. 
After incubation, pelleting and aspiration of the su-
pernatant, apoA-I is the dominant protein bound to the 
nanoparticles, but serum albumin is often a contaminant. 
Cedervall et al. showed [20] that serum albumin dissoci-
ates much faster from the copolymer particle surface than 
apoA-I. This difference allows for serum albumin to be 
washed away while the major fraction of apoA-I remains 
attached to the copolymer particles.  
3.3. Role of Salt and Buffer Composition in the 
Nanoparticle-Washing Step 
To optimize the washing procedures, buffers with dif-
ferent NaCl concentrations, 0.15, 0.5, 1.0, and 2.0 M, 
were tested. As shown in Figure 3 there are no dramatic 
differences after the first wash, while after the second 
wash 1 and 2 M NaCl leads to more efficient removal of 
serum albumin than 0.15 and 0.5 M NaCl.  In the third 
wash, there is too little protein to allow for any quantita-
tive comparison, and there is no obvious difference in the 
amount of apoA-I retrieved from the nanoparticles. Fi- 
gure 3 also shows that the amount of apoA-I that is lost 
in the three wash steps is virtually the same for all four 
NaCl-concentrations. For simplicity 10 mM Tris/HCl pH 
7.5, 1 mM EDTA, 0.15 M NaCl was selected for both the 
sample incubation and washing steps. This buffer condi-
tion is also favorable for the subsequent purification 
steps (see below). 
3.4. Optimization of the Elution Step 
In order to optimize the elution of apoA-I from the  
 
 
Figure 3. Optimization of the NaCl concentration during 
the washing steps. SDS PAGE of the protein eluted from the 
nanoparticle pellet after three washes (lanes 2-5), and of the 
supernatant from the 1st (lanes 7-10), 2nd (lanes 11-14) and 
3rd (lanes 15-18) washing steps. The NaCl concentration 
was 0.15, 0.5, 1.0 or 2.0 M from left to right among the four 
samples at each step. 
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nanoparticles, at least two factors are necessary to con-
sider in order to maximize the protein yield. The effi-
ciency of the elution is, of course, important for the final 
protein yield. However, the buffer composition after the 
elution is also important for the protein yield as it will 
affect the subsequent purification steps. Buffers with 
high salt concentration, high and low pH, different de-
tergents, or urea were tested for their elution efficiency 
(Figure S3 in supplementary material), determined as the 
highest amount of protein in the gel bands. The highest 
amount of apoA-I was eluted using detergents, followed 
by 3 M NaCl, followed by 6 M urea. At lower NaCl 
concentration, or at pH 4 or 9.2, little or no elution could 
be observed. Urea was chosen as eluant for the purifica-
tion scheme as it allows the eluted proteins to be loaded 
directly onto an ion exchange column without changing 
the buffer. The detergents, although they are the best 
eluants, were not chosen as it could be difficult to remove 
them from the protein, resulting in a lower purity of the 
final product. 
Figure 1 shows the different stages in the purification 
of apoA-I schematically. The amount of eluted apoA-I 
decreases in each step of elution with 6 M urea (Figure 1, 
Lanes 3-5). The small amount of apoA-I remaining in the 
third urea eluate does not motivate a fourth urea step. 
3.5. Ion Exchange Chromatography 
After elution of apoA-I from the copolymer particles, 
ion-exchange (DEAE) chromatography is used to sepa-
rate apoA-I from impurities, mainly the proteins apoli-
poprotein E and serum albumin [19] and copolymer par-
ticle fragments and to remove urea and change the buffer. 
Before loading onto the DEAE-column the pooled sam-
ple is diluted 10 times with 10 mM phosphate buffer pH 
7.5, 1 mM EDTA, to reduce the NaCl concentration. 
Bound molecules are eluted from the DEAE-column in a 
stepwise manner. Non-protein substances are eluted in 
buffer with 50 mM NaCl, apoA-I is eluted in buffer with 
0.15 M NaCl, and serum albumin elutes in 3 M NaCl, 
which regenerates the column (serum albumin would 
elute much earlier if a gradient elution profile were 
used). 
If the first step (elution in 50 mM NaCl) is not in-
cluded, something that scatters light under 270 nm is co- 
eluted with apoA-I (data not shown). The fraction from 
the first elution step does not contain protein (no visible 
bands in a coomassie stained gel). Analysis by NMR 
spectroscopy (data not shown) indicates an interaction 
between buffer molecules and very large molecules and/ 
or a slight increase in the solution viscosity evidenced as 
a slower tumbling of the molecules and a broader peak 
[21]. The most probable explanation for the observed phe- 
nomena is that the eluted fraction consists of fragments 
of the copolymer particles. However, this has to be in-
vestigated further. 
3.6. Maximizing ApoA-I Yield 
Figure 3 shows that even though apoA-I has a high af-
finity for the copolymer particle surface, a large fraction 
of the apoA-I is washed away in the first washing step. 
Two experiments were conducted to maximize the yield 
of purified apoA-I. The effect of the copolymer particle 
concentration was checked by keeping the total sample 
volume and the total plasma concentration constant while 
the concentration of particles was varied. After incuba-
tion, the same amount (by weight) of copolymer particles 
was removed from each sample and the amount of bound 
apoA-I analyzed by SDS PAGE after elution in SDS 
loading buffer. The results show that the total binding of 
apoA-I increases with the particle concentration (Figure 
S1, supplementary material), hence, one limiting factor 
in the yield is the available particle surface area. To con-
firm this result a second experiment was conducted in 
which different amounts of lyophilized copolymer parti-
cles were dispersed in the same volume of plasma. The 
trend of increasing yield of apoA-I with increasing 
amount of available surface area was confirmed (Figure 
S2, supplementary material). Table 1 shows the amounts 
of purified apoA-I for two experiments with different 
particle concentrations. The purification efficiency, in per- 
cent, is calculated assuming that the concentration of 
apoA-I in the original plasma is ~1 mg/ml. These results 
show that it is not the apoA-I concentration in blood that 
is the limiting factor for the yield of purified apoA-I, but 
the solubility (dispersability) of the copolymer particles  
 
Table 1. Comparison of the efficiency of the copolymer 
nanoparticles at purifying apoA-1 from plasma with two 
different dispersion methods—with TBS as an intermediate 
step, or direct dispersion in plasma. 
 1a 2b 
Theoretical max apoA-I (mg)c 3.6 2.2 
Particles (mg)d 45 22 
Plasma/particles (ml/mg)e 0.08 0.1 
Amount purified apoA-I (μg)f 224 277 
Purification efficiency (%)g 6 13 
Purified apoA-I/amount particles (μg/mg)h 5 13 
aCopolymer particles first dispersed in TBS before mixing with plasma; 
bCopolymer particles directly dispersed in plasma; cCalculated at a nominal 
apoA-I concentration of 1 mg/ml plasma; dTotal amount of copolymer parti-
cles used in the experiment; eRatio between plasma and copolymer particles 
in the experiment; fTotal amount of purified apoA-I in the experiment; 
gPurification efficiency in percent purified apoA-I compared to the nominal 
apoA-I concentration; hAmount purified apoA-I per mg copolymer particles. 
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Figure S1. ApoA1 retrieved with different amounts of 
polymer particles added to 210 μl plasma in a total volume 
of 910 μl. Lanes 1, 2, 3, 4, 5, 6, 7, and 8 represent 0.007, 0.07, 
0.14, 0.35, 0.7, 1.4, 2.1, and 7.0 mg co-polymer particles, 
respectively. The 0.35, 0.7, 1.4, 2.1 and 7.0 mg samples con-
tain protein from an identical amount of polymer particles. 
 
 
Figure S2. Lanes 1, 2, 3, and 4 represent 10, 5, 2.5 and 1 mg 
co-polymer nanoparticles, respectively, that were dissolved 
in 1 ml plasma. Washed with 3 x 1000, 500, 250 and 100 μL, 
respectively, of 10 mM trizma/HCl pH 7.5, 1 mM EDTA, 
0.15 M NaCl. The pellets were dissolved in 100, 50, 25 and 
10 μL SDS-loading buffer, respectively, and 10 μL of each 
sample was loaded on the electrophoresis gel. 
 
 
Figure S3. Elution of apoA1 from the co-polymer particles 
using different agents. Lanes 1, 2, and 3 are eluates in 1, 2, 
and 3 M NaCl, respectively, lane 4 the eluate with 2% triton, 
lane 5 with 2% tween-20, lane 6 with 6 M urea, lane 7 10 
mM sodium acetate buffer, pH 4, lane 8 10 mM Tris/HCl 
pH 9.2, and lane 9 buffer with 2% SDS. All eluates except in 
lanes 7 and 8 contain 10 mM Tris/HCl pH 7.5. 
 
in plasma and thus the amount of available surface area. 
The highest concentration of particles that can be dis-
persed in plasma is ~10 mg per ml, as above at this con-
centration particle aggregation occurs, and thus the over-
all surface area available for bind decreases again. 
3.7. Lipid-Free ApoA-I 
Preliminary results indicate that the particles bind apoA-I 
together with lipids in the first step of the purification 
scheme. As the goal was to purify lipid free apoA-I, the 
final purified sample was checked for cholesterol and 
triglycerides with commercial enzyme-based detection 
kits (see SI). No lipids were detected in the purified 
apoA-I samples suggesting that the purified apoA-I is 
lipid free. 
3.8. Comparison with Commercial ApoA-I  
Integrity, Structure and Function 
The purified apoA-I was compared to commercially 
available apoA-I. On a coomassie stained 1D SDS-PAGE 
gel, the commercial protein gives rise to three bands, 
while the protein purified by the method described here 
gives rise to one band on the same gel with similar 
amounts of sample loaded, as shown in Figure 4(a). The 
identity of the purified apoA-I has been confirmed re-
peatedly by mass spectrometry [21,22]. The apparent 
differences in size between the three bands in the com-
mercial sample of apolipoprotein A-1 may be due to 
modifications or proteolysis. Another explanation may be 
that the copolymer particles specifically target a sub-
population of apoA-I, for example, the fraction with oxi-
dized side chains. This is less likely as the apoA-I found 
in the wash fractions has the same mobility as the puri-
fied protein. Thus, the three bands in commercial apoA-I 
are most likely due to the harsh conditions used during 
the existing purification process, whereas the protocol 
presented here leads to a homogeneous protein prepara-
tion. 
Three different spectroscopic methods, UV absorbance, 
intrinsic tryptophan fluorescence and far UV circular 
dichroism spectroscopy, are used to evaluate and com-
pare the structure of apoA-I purified via the method pre-
sented here with commercial apoA-I. The UV absorb-
ance spectra, Figure 4(b), gives information on local 
structural changes around aromatic amino acids; the in-
trinsic tryptophan fluorescence spectra, Figure 4(c), gives 
information on changes in the tertiary structure; and the 
far UV circular dichroism spectra, Figure 4(d), reports 
on changes in the secondary structure. In all of the spec-
tra there are no or very small deviations between the 
commercial and purified apoA-I, indicating that the terti-
ary and secondary structure of apoA-I are essentially the 
same in the two samples.  
The phospholipids binding function of the purified 
apoA-I was examined by reconstitution of phospholip-
ids:apoA-I vesicles. Figure S4 shows that the copolymer 
particle purified apoA-I interacts with and forms vesicles 
together with phospholipids in a similar way to that 
shown previously for apoA-I purified with a traditional 
purification protocol [18].   
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(a)                                                   (b) 
 
 
(c)                                                   (d) 
Figure 4. Comparison between commercial apoA-I and the apoA-I purified by the method described here. (a) Lane 1 = mo-
lecular weight standards with the Mw of the proteins given to the left, lane 2 = commercial apoA-I, lane 3 = apoA-I purified 
in this work. In (b), (c) and (d), dark grey = commercial apoA-I and light grey = purified apoA-I. (b) absorbance, (c) fluores-
cence and (d): circular dichroism spectra. 
 
 
Figure S4. ApoA1 was mixed with labelled PL in order to 
generate rHDL. The sample was analyzed by gelfiltration. 
Eluted fractions were analyzed by scintillation counting and 
apoA1 ELISA. 
 
4. Conclusions 
Copolymer nanoparticles offer efficient and facile puri-
fication of apoA-I from complex protein mixtures, such 
as plasma. The purification scheme presented here dra-
matically reduces the time needed for purification. The 
final yield of pure apoA-I is up to 13 mg/g nanoparticles, 
which is comparable to other affinity chromatography 
systems. The particles also bind apolipoprotein E, A-IV, 
and A-II with high specificity. These apolipoproteins are 
in much lower concentrations in plasma and are therefore 
a challenge to purify. However, in a scaled up purifica-
tion protocol it should be possible to purify also these 
proteins using the copolymer particles. Additionally, 
slight modification of the comonomer ratio could be used 
to optimize the particles for selective binding of these 
proteins. 
The copolymer particles are easy and inexpensive to 
produce and their physical and chemical characteristics 
(including surface charge and/or hydrophobicity or sur-
face energy) are easy to vary. Additionally, the particles 
can be modified with ligands with high specificity for 
selected target proteins. These features make the co-
polymer particles an attractive choice for purification of 
proteins, not limited to apolipoproteins. 
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